Expert Perspectives in Pulmonary Arterial Hypertension: Health-System Considerations

Activity Description

This activity will provide health-system pharmacists and nurses and specialty pharmacy professionals with the foundational knowledge needed to manage PAH patients. Current and emerging treatments will be discussed along with their place in therapy, dosing, and monitoring strategies. Management of hospitalized PAH patients will be highlighted and include the decision-making process for treatment decisions in acute and emergency care settings. The activity will conclude with a focus on the roles of the collaborative care team during transitions of care to ensure patient-centered care and good outcomes.

Target Audience

The target audience for this activity includes pharmacists and nurses.

Learning Objectives

At the completion of this activity, the participant will be able to:

  • Examine the roles of the nitric oxide, endothelin, and prostacyclin pathways in pulmonary arterial hypertension (PAH).
  • Discuss recent data for current and emerging individualized treatments for PAH by mechanism of action, mode of delivery, safety, and monitoring parameters.
  • Outline management strategies for PAH patients in the health-system setting, including therapeutic substitutions and transitions from oral to intravenous treatments.
  • Describe best practices for the collaborative care team during transitions of care.

Faculty

Matt Casciano, PharmD, BCPS
Clinical Pharmacy Specialist - Pulmonary
UCHealth University of Colorado Hospital
Aurora, Colorado

Pol-Andre Senecal, MSN, NP, ACNP
Nurse Practitioner
Colorado Pulmonary Intensivists
APP Intensivist
Littleton Adventist Hospital
Littleton, Colorado

CME/CE Accreditation

Release Date: December 2, 2020
Expiration Date: December 15, 2021

ACPE Credit Designation (Pharmacist CE)

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-20-530-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
 


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

ProCE and CCO planners and faculty have reported the following financial relationships or products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:
James C. Coons, PharmD, FCCP, BCCP (peer reviewer) has disclosed that he has received fees for research support from United Therapeutics.
Matt Casciano, PharmD, BCPS has no relevant conflicts of interest to report.
Pol-Andre Senecal, MSN, NP, ACNP has no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Funding

This activity is supported by an educational grant from Actelion.

 

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.